Biological E Limited.

FDA Approves Bavarian Nordic's Vimkunya, First Chikungunya Vaccine for Adolescents

5 months ago

• The FDA has approved Vimkunya, a chikungunya vaccine developed by Bavarian Nordic, for individuals aged 12 and older. • Vimkunya is the first virus-like particle (VLP) single-dose chikungunya vaccine approved in the U.S., offering a new preventative option. • Clinical trials showed Vimkunya induced neutralizing antibodies in up to 97.8% of vaccinated individuals within 21 days. • Commercial availability of Vimkunya in the U.S. is expected in the first half of 2025, with launches in key European markets anticipated.